Health Secretary Robert F
Its important to reiterate that the scientific evidence supporting these benefits is limited, and individual results may vary
T.SpaceyS
Officially, the FDA cites: Insufficient large-scale clinical trials Concerns about consistency, sourcing, and manufacturing standards The need to meet formal drug approval requirements Critics argue (fairly) that this system: Favors large pharmaceutical companies Makes it hard to approve naturally occurring peptides Leaves promising, low-risk compounds in regulatory limbo The short version: This FDA restrictive regulatory change of mind wasnt driven by a sudden safety scare, it was driven by regulatory process and economics
However, in patients with pernicious anaemia or malabsorption, these stores cannot be replenished through diet, making regular injections essential
Who should avoid GHK-CU Wilson's disease or copper metabolism disorders Active malignancies (until more research exists) Pregnancy and breastfeeding Known copper sensitivity or allergy Those unable to maintain sterile injection technique When uncertain, consult a healthcare provider familiar with peptide research
